Details

Autor(en) / Beteiligte

• Cohen, Mikael
• Thomel-Rocchi, Océane
• Siva, Aksel
• Okuda, Darin T
• Karabudak, Rana
• Efendi, Hüsnü
• Terzi, Murat
• Carra-Dalliere, Clarisse
• Durand-Dubief, Francoise
• Thouvenot, Eric
• Ciron, Jonathan
• Zephir, Helene
• Bourre, Bertrand
• Casez, Olivier
• De Seze, Jérôme
• Moreau, Thibault
• Neau, Jean-Philippe
• Pelletier, Daniel
• Kantarci, Orhun
• Tutuncu, Melih
• Derache, Nathalie
• Bensa, Caroline
• Louapre, Celine
• Benoit, Jeanne
• Landes-Chateau, Cassandre
• Lebrun-Frenay, Christine

Titel

Impact of COVID-19 vaccination or infection on disease activity in a radiologically isolated syndrome cohort: The VaxiRIS study

Ist Teil von

• Multiple sclerosis, 2023-08, Vol.29 (9), p.1099-1106

Ort / Verlag

London, England: SAGE Publications

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Background: Vaccination in patients with multiple sclerosis (MS) treated with immunosuppressive drugs is highly recommended. Regarding COVID-19 vaccination, no specific concern has been raised. Objectives: We aimed to evaluate if COVID-19 vaccination or infection increased the risk of disease activity, either radiological or clinical, with conversion to MS in a cohort of people with a radiologically isolated syndrome (RIS). Methods: This multicentric observational study analyzed patients in the RIS Consortium cohort during the pandemic between January 2020 and December 2022. We compared the occurrence of disease activity in patients according to their vaccination status. The same analysis was conducted by comparing patients’ history of COVID-19 infection. Results: No difference was found concerning clinical conversion to MS in the vaccinated versus unvaccinated group (6.7% vs 8.5%, p > 0.9). The rate of disease activity was not statistically different (13.6% and 7.4%, respectively, p = 0.54). The clinical conversion rate to MS was not significantly different in patients with a documented COVID-19 infection versus non-infected patients. Conclusion: Our study suggests that COVID-19 infection or immunization in RIS individuals does not increase the risk of disease activity. Our results support that COVID-19 vaccination can be safely proposed and repeated for these subjects.